Company intelligence / Profile preview
Edimer Pharmaceuticals
Cambridge, Massachusetts, United Statesorpha.net ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
Edimer Pharmaceuticals developed EDI200 (efsudenermin alfa), which received FDA Fast Track designation. The company conducted Phase 2 clinical trials for treating X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations.
- Therapeutic areas
- Rare Diseases
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Edimer Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Edimer Pharmaceuticals.